This may be useful for others, once the verdicts are in on this:
XL184 is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2. MET is a receptor tyrosine kinase that plays key roles in cellular proliferation, migration, and invasion as well as angiogenesis1. These biological processes contribute to the transformation, progression, survival and metastasis of cancer cells1. The MET pathway is frequently activated in tumors through MET amplification, mutation, and overexpression, as well as through overexpression of its ligand HGF1. Expression of VEGF has been observed in a variety of cancers and has been associated with the stimulation and growth of new blood vessels to support the tumor2,3. MET and VEGFR2 are important driving forces in angiogenesis, implicated in the ability of tumors to overcome hypoxia following angiogenesis inhibition4,
Cut off the blood supply, new blood vessels and help halt the cancer, has been known about for years...hopefully this intervention shows usefulness. It appears they are entering Phase III soon and 'if' it gets beyond Phase III and into final phase...then it will become approved. Alot of drugs or protocols get killed in Phase II or Phase III...and not because the item is unuseful or whatever...it costs an absolute fortune to run these clinical Phase trials and some companies run out of money or resolve or other possible considerations (some might be less than righteous reasons, we have profits, lobbyist's and landslides of contributing factors)-FYI.
Last edited by neutrondbob; 04-08-2011 at 11:32 AM.
Reason: additional info
Exelixis releases encouraging Cabozantinib phase II trial interim data
PBR Staff Writer Published 18 February 2011
Exelixis, a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for cancer treatment, has updated interim data of an ongoing phase 2 adaptive randomized discontinuation trial evaluating the effects of cabozantinib (XL184) treatment in patients with metastatic castration-resistant prostate cancer (CRPC).
Cabozantinib is an inhibitor of tumor growth, metastasis and angiogenesis. It simultaneously targets MET and VEGFR2 - key kinases involved in the development and progression of many cancers.
Resultant data supports the findings that cabozantinib reduces or stabilizes metastatic bone lesions in nearly all patients, reduces bone pain and narcotic analgesic medication, shows high rates of complete or partial bone scan resolution (85%), and increases hemoglobin in anemic patients.
Cabozantinib has also shown encouraging early signals of durable clinical benefit in docetaxel-na´ve and pretreated patients.
DOB Sept. 1947. Prostate cancer Gleason 7 (3+4), PSA 5 in Oct 2010. Cryoablation Jan. 2011. Had some complications.
Experienced nocturia, irritable bladder summer 2011. "Agent Orange"compensation from VA Oct 2011.
PSA: .05 01/26/2012, .06 6/26/2012, .04 12/24/2012, .04 6/26/13, .05 1/27/14, .05 10/21/14, .04 10/15
I am eating vegan mostly plus a little fish. Take some supplements.
(Any advice given is the personal opinion of a layman and is not intended to replace the advice of a health professional.)
Thanks for adding to it and now we have the name of it...another hard to pronounce new drug...they have so many drugs out there, they have to get creative on new names. I hope this drug has a realistic price tag on it.